Bacillus coagulans GBI-30, 6086 and Reduced C-Reactive Protein Levels

• Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial

  • 2010-01-12
  • RCT · n = 45
  • BMC Complementary and Alternative Medicine 10(1)
  • • D. Mandel
    • K. Eichas
    • J. Holmes

  • PubMed: 20067641
  • DOI: 10.1186/1472-6882-10-1

  13 Insights on

  • Reduced C-Reactive Protein Levels

  • High evidence
  • Highly Cited
  • Rigorous Journal

  Bacillus coagulans GBI-30, 6086 treatment resulted in greater improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to walk 2 miles, reach, and participate in daily activities.

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  once a day

• Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial.

  • 2014-10
  • RCT
  • AIDS research and human retroviruses 30(10)
  • • Otto O Yang
    • Theodoros Kelesidis
    • Robert Cordova
    • Homayoon Khanlou

  • PubMed: 25127924
  • DOI: 10.1089/aid.2014.0181

  9 Insights on

  • Reduced C-Reactive Protein Levels

  • High evidence
  • Clinical

  None of the biomarkers showed significant changes on probiotic treatment or between-group differences in change

  Effect

  Neutral

  Effect size

  Small

  Significant

  No

  Dose

  1 capsule (presumed, exact probiotic concentration not stated in abstract)